The legalisation of medical cannabis marks an exciting time in healthcare. It’s a brand new industry with huge opportunities. Cymra Life Sciences combines pharmaceutical industry expertise and plant based science to deliver the high quality whole plant medical cannabis to the Australian market.
The philosophy of Cymra places innovation and Intellectual Property at the core of our business around genetics and pharmaceutical drug development
In 2018, Cymra secured licences from the Office of Drug Control for both the cultivation and manufacturing of cannabis oil, one of just a few Australian companies to own the full supply chain including cultivation, production, manufacturing and distribution.
In 2021, Cymra secured the necessary Office of Drug Control permits to cultivate and manufacture cannabis and sell to the world under GMP.
Cymra has completed a Phase II clinical trial and is now commencing a Phase III clinical trial in assessing cannabis as a 2nd line therapy for chronic pain patients against a placebo.
Want to keep up to date with the latest Medical Cannabis Information in Australia and from around the world?
We will send you informative information from time to time so you can learn about cannabis and if it can help you.
From time to time our team publishes interesting content that we feel is valuable to the Investor community
If you are an existing investor of Cymra Life Sciences you can login using tehe button below or by going to the Investor Centre page.